For research use only. Not for therapeutic Use.
Alniditan(CAT: I013587) is a selective serotonin 5-HT1 receptor agonist developed for the treatment of acute migraines. By stimulating 5-HT1 receptors, primarily located in cranial blood vessels, it induces vasoconstriction and reduces the release of pro-inflammatory neuropeptides, alleviating migraine symptoms. Alniditan is particularly significant in neurological and vascular research, where it aids in understanding the role of serotonin receptors in migraine pathophysiology and in developing targeted migraine therapies. Its specificity for 5-HT1 receptors positions it as a valuable compound for advancing treatments aimed at acute migraine relief and related neurological disorders.
| Catalog Number | I013587 |
| CAS Number | 152317-89-0 |
| Molecular Formula | C₁₇H₂₆N₄O |
| Purity | ≥95% |
| Target | Neuronal Signaling |
| Solubility | DMSO |
| IUPAC Name | N-[[(2R)-3,4-dihydro-2H-chromen-2-yl]methyl]-N//'-(1,4,5,6-tetrahydropyrimidin-2-yl)propane-1,3-diamine |
| InChI | InChI=1S/C17H26N4O/c1-2-6-16-14(5-1)7-8-15(22-16)13-18-9-3-10-19-17-20-11-4-12-21-17/h1-2,5-6,15,18H,3-4,7-13H2,(H2,19,20,21)/t15-/m1/s1 |
| InChIKey | QVSXOXCYXPQXMF-OAHLLOKOSA-N |
| SMILES | C1CNC(=NC1)NCCCNCC2CCC3=CC=CC=C3O2 |
